Jan 22, 2026 08:45AM

Jan 9, 2026 08:45AM

Dec 9, 2025 08:04AM

Dec 2, 2025 08:32AM

Nov 13, 2025 04:08PM

Nov 10, 2025 08:30AM

Oct 29, 2025 08:37AM PDS Biotech seeks expedited approval pathway for head and neck cancer drug

Sep 18, 2025 08:45AM

Aug 29, 2025 04:16PM

Aug 13, 2025 07:25AM

Jul 11, 2025 06:38AM

Jul 10, 2025 08:03AM

Jun 11, 2025 06:39AM

Jun 2, 2025 08:03AM PDS Biotechnology (PDSB) Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers

May 22, 2025 05:32PM

May 14, 2025 04:23PM

Mar 28, 2025 06:40AM

Mar 10, 2025 06:51AM

Mar 7, 2025 08:45AM

Feb 27, 2025 08:00AM

Feb 24, 2025 08:00AM PDS Biotechnology (PDSB) Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 5, 2025 08:02AM

Nov 14, 2024 08:00AM

Oct 3, 2024 06:59AM

Oct 2, 2024 08:02AM

Sep 16, 2024 07:01AM

Aug 13, 2024 08:10AM

Aug 1, 2024 07:45AM PDS Biotechnology (PDSB) Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jun 12, 2024 08:01AM

Jun 12, 2024 07:37AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All